CDC's latest Morbidity and Mortality Weekly Report showed that US adults of non-Hispanic Black, American Indian or Alaska Native, and Hispanic race/ethnicity exhibited significantly higher influenza hospitalization rates and lower vaccination coverage compared with White adults.
Racial and ethnic disparities persist regarding severity and vaccination coverage of influenza, according to the latest CDC Morbidity and Mortality Weekly Report.
Characterized as a contagious respiratory disease, CDC estimates indicate that influenza resulted in 9 million to 41 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 52,000 deaths annually during 2010-2020. Some racial and ethnic minority groups have historically shown higher rates of severe influenza compared with White individuals, noted researchers, as well as lower vaccination rates for the disease.
“Vaccination provides important protection from influenza illness and its potential complications,” they explained. “For example, during the 2019-20 season, influenza vaccination prevented an estimated 7.5 million influenza illnesses, 105,000 influenza-associated hospitalizations, and 6300 influenza-associated deaths.”
Authors conducted an analysis to further explore influenza hospitalization rates and vaccination coverage by race and ethnicity from 2010-2011 through the 2021-2022 seasons. They also investigated influenza vaccination coverage stratified by race and ethnicity and health care access variables for the 2021–2022 season and possible reasons for observed disparities.
The analysis derived data from population-based surveillance for laboratory-confirmed influenza-associated hospitalizations in selected states participating in the Influenza-Associated Hospitalization Surveillance Network (FluSurv-NET) from the 2009-2010 through 2021-2022 influenza seasons (excluding 2020-2021) and influenza vaccination coverage data from the Behavioral Risk Factor Surveillance System (BRFSS) from the 2010-2011 through 2021-2022 influenza seasons.
“BRFSS is a state-based random-digit–dialed cellular and landline telephone survey that collects information on various health conditions and risk behaviors from one randomly selected adult aged 18 years or older in a household,” the authors explained.
From 2009-2010 through 2021-2022 (excluding 2020-2021), age-adjusted influenza-associated hospitalization rates per 100,000 population were shown to be higher among non-Hispanic Black (Black) (rate, 78.2; rate ratio [RR], 1.8), American Indian or Alaska Native (AI/AN) (rate, 54.6; RR, 1.3), and Hispanic (rate, 50.3; RR, 1.2) adults compared with the rate among White adults (rate, 43.0), whereas Asian or Pacific Islander (API) adults showed reduced rates (rate, 34.5).
Some variations in age-adjusted influenza-associated hospitalization rates per 100,000 population were cited by influenza season:
Overall, vaccination coverage in the 2021-2022 influenza season was 49.4% among adults, which varied by race and ethnicity. Specifically, influenza vaccination coverage for the 2021-2022 influenza season showed that coverage was lower among Hispanic (37.9%), AI/AN (40.9%), Black (42.0%), and other/multiple race (42.6%) adults compared with that among White (53.9%) and non-Hispanic Asian (Asian) (54.2%) adults.
Moreover, coverage was found to be consistently higher among White and Asian adults compared with that among Black and Hispanic adults since the 2010-2011 season. Disparites in vaccination coverage by race and ethnicity were reported among those with and without medical insurance, a personal health care provider, and a routine medical checkup in the past year.
Compared with White adults, Hispanic adults were less likely to have medical insurance, and Hispanic, AI/AN, and multiracial adults and adults of other races were less likely to have a personal health care provider and a medical checkup in the past year.
Among adults with medical insurance, a personal health care provider, and a routine medical checkup in the past year, and in most age and education strata, influenza vaccination coverage remained higher among White adults than among Black, Hispanic, AI/AN, and multiracial adults and adults of other races.
In response to the study findings, researchers said that health care providers should assess patient vaccination status at all medical visits and offer all recommended vaccines.
“Tailored programmatic efforts to provide influenza vaccination through nontraditional settings, along with national and community-level efforts to improve awareness of the importance of influenza vaccination in preventing illness, hospitalization, and death among racial and ethnic minority communities might help address health care access barriers and improve vaccine confidence, leading to decreases in disparities in influenza vaccination coverage and disease severity,” they concluded.
Reference
Black CL, O’Halloran A, Hung M, et al. Vital Signs: Influenza hospitalizations and vaccination coverage by race and ethnicity—United States, 2009–10 through 2021–22 influenza seasons. MMWR Morb Mortal Wkly Rep. Published online October 18, 2022. doi:10.15585/mmwr.mm7143e1
5 Things Everyone Should Know for National Immunization Awareness Month
August 1st 2025National Immunization Awareness Month highlights the importance of lifelong vaccination to prevent diseases, a practice that has averted millions of deaths, proven to be a cost-effective public health strategy, and offers crucial protection even to individuals who are immunocompromised.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More